Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives

Toll-like receptors (TLRs) serve as the body’s first line of defense, recognizing both pathogen-expressed molecules and host-derived molecules released from damaged or dying cells. The wide distribution of different cell types, ranging from epithelial to immune cells, highlights the crucial roles of TLRs in linking innate and adaptive immunity. Upon stimulation, TLRs binding mediates the expression of several adapter proteins and downstream kinases, that lead to the induction of several other signaling molecules such as key pro-inflammatory mediators. Indeed, extraordinary progress in immunobiological research has suggested that TLRs could represent promising targets for the therapeutic intervention of inflammation-associated diseases, autoimmune diseases, microbial infections as well as human cancers. So far, for the prevention and possible treatment of inflammatory diseases, various TLR antagonists/inhibitors have shown to be efficacious at several stages from pre-clinical evaluation to clinical trials. Therefore, the fascinating role of TLRs in modulating the human immune responses at innate as well as adaptive levels directed the scientists to opt for these immune sensor proteins as suitable targets for developing chemotherapeutics and immunotherapeutics against cancer. Hitherto, several TLR-targeting small molecules (e.g., Pam3CSK4, Poly (I:C), Poly (A:U)), chemical compounds, phytocompounds (e.g., Curcumin), peptides, and antibodies have been found to confer protection against several types of cancers. However, administration of inappropriate doses of such TLR-modulating therapeutics or a wrong infusion administration is reported to induce detrimental outcomes. This review summarizes the current findings on the molecular and structural biology of TLRs and gives an overview of the potency and promises of TLR-directed therapeutic strategies against cancers by discussing the findings from established and pipeline discoveries

An improved method for experimental induction of ulcerative colitis in Sprague Dawley rats

Ulcerative colitis (UC) is a chronic inflammatory manifestation of the human colon that is linked with colorectal cancer. Development of an appropriate animal model is crucial to study the immunopathophysiology of UC wherein chemical induction is the most popular method of choice. However, unavailability of an optimum experimental model limits the success of this method. The present study aims to establish an optimized model for acetic acid-induced colitis in Sprague Dawley rats. Response Surface Methodology (RSM) with a six-factors Box-Behnken design was employed to generate an improved method of inducing UC in rat, predicting the case statistics, apposite investigation of quadratic response surfaces, and construction of a second-order polynomial equation. UC was diagnosed through three responses viz. weight loss, severity of diarrhea, and appearance of blood in the stool. Analysis of variance alongside RSM jointly revealed that induction of UC can be achieved with highest probability using the combination of parameters that includes 120 gm body weight, 1.5 ml of 4% acetic-acid v/v in distilled water with a single dose of treatment for 24 h including a pre-induction of 5 mins. This optimized UC-induction model was validated in-vivo through disease scoring index and hematological assessments with satisfactory level of desirability. • An improved experimental method for inducing ulcerative colitis (UC) in Sprague Dawley rats has been developed. • Box-Behnken Design-fitted Response Surface Methodology (RSM) was implicated in optimizing the experimental parameters for generating UC. • This statistically optimized and experimentally validated method resembles the recipe for the generation of UC in animal model with the highest possible desirability